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This article aims to review glutamine metabolism and its effects on the immune response. Selected topics are
addressed, particularly the effect of glutamine on cell survival and proliferation, as well as its importance in some
biochemical pathways. The impact of glutamine on muscle, intestine, and liver metabolism are described, and a
special section about glutamine regulation of the immune response is included. In this context, the modulation
of glutamine on relevant signaling pathways as nuclear factor kappa B (NF-kB), mitogen-activated protein kinases
(MAPKs), and heat shock protein and the influence of this amino acid on cell migration and adhesion molecules are
highlighted. Some important immune response pathways modulated by glutamine were described as its action in
critically ill patients. In summary, this review describes some important actions of glutamine, and a range of
reactions and modulatory effects in different organs, which may inform new therapeutic strategies. However,
further studies are necessary to provide information about glutamine use, especially about situations in which
it can be better used as well as fine-tuning dose and administration.
Keywords: Glutamine, Immune response, Nuclear factor kappa BBackground
Glutamine is an α-amino acid and is the most abundant
free amino acid in the body. The first description about
the glutamine importance was made by Ehrensvard et al.
[1] which described the importance of glutamine to cell
survival and proliferation; however, a more detailed
description about glutamine actions were made by Eagle
et al. 1966 [2]. At the most basic level, glutamine acts as
an important fuel in the cells and tissues and a high rate
of glutamine uptake is characteristic of rapidly dividing
cells such as enterocytes, fibroblasts, and lymphocytes
[2, 3]. The extracellular concentration of glutamine is
around 0.7 mM, the most abundant extracellular amino
acid in vivo, while the most abundant intracellular* Correspondence: hemato@usp.br
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ranging between 2 and 20 mM [3].
The most important enzymes related to the glutamine
metabolism are glutamine synthetase and glutaminase.
Glutamine synthetase catalyzes the conversion of glu-
tamate to glutamine using ammonia as nitrogen source
(glutamate + NH4
+ + ATP ~ > glutamine + ADP + Pi). Glu-
taminase is an enzyme that catalyzes the hydrolysis of
glutamine to glutamate and an ammonium ion [3, 4]
(Fig. 1). The immediate product of glutamine metabol-
ism is L-glutamate. In a transamination reaction,
glutamate can donate its amino group for new amino
acid synthesis and deaminated to 2-oxoglutarate [3].
Glutamine is involved in various biochemical pathways.
Some of those are providing energy substrate, serving as a
precursor to amino acid synthesis, the nitrogen donor in
the formation of nucleic acids, aiding in the synthesis of
intracellular proteins, and acting as an essential contribu-
tion to the acid-base balance [2–4].
Glutaminolysis provides metabolic intermediates for
synthetic pathways of macromolecules and providesle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Fig. 1 Glutamine metabolism, glutamine synthetase catalyzes the conversion of glutamate to glutamine using ammonia as nitrogen source, and
glutaminase is an enzyme that catalyzes the hydrolysis of glutamine to glutamate and ammonium ion
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pyrimidines, which are necessary for the formation of
DNA and RNA [5, 6]. Glutamine can generate pyruvate
by a route involving conversion to glutamate, then by
the activity of glutamate dehydrogenase in 2-
oxoglutarate, which enters TCA cycle, followed by the
action of NADP+-dependent enzyme that catalyzes the
conversion of malate into pyruvate. The pyruvate may
be converted to L-alanine by amination, via lactate
dehydrogenase in to lactate and then released, or it may
enter the tricarboxylic acid (TCA) cycle. This process
generates NADH and FADH2 which may be used in the
electron transport chain in the mitochondria, thereby
promoting ATP synthesis [7].
Glutamine also can be metabolized by the gamma-
glutamyl cycle and is required for glutathione synthesis.
Glutathione is a tripeptide produced from glutamate,
glycine, and cysteine, which can act on cells as a cofactor
for the cytoplasmic enzyme [8]. In addition, the glutam-
ine metabolism, via TCA cycle, promotes action of
NADP+-dependent enzyme, which increases NADPH
production, consequently increasing the GSH/GSSG
(glutathione reduced/glutathione oxidized) ratio [7].
Glutamine: muscle metabolism
The skeletal muscle is the major tissue responsible for glu-
tamine synthesis in the body [9, 10]. Glutamine synthesis
in the skeletal muscle not only preserves lean mass butalso maintains plasma glutamine concentration in the
body [9, 11, 12]. In humans, glutamine is the main intra-
cellular amino acid (19.45 mM intracellular H20 for the
skeletal muscle). The skeletal muscle produces glutamine
at high rates, on average 50 mmol/h, higher than any
other amino acid. This high rate is essential to maintain
plasma glutamine homeostasis and glutamine stores in the
muscle [13, 14].
The key enzymes in the metabolism of glutamine,
glutamine synthetase (GS), and glutaminase (GA) are
regulated by transcriptional and post-transcriptional
mechanisms. Only GS is responsible for de novo synthe-
sis of glutamine. GS expression is mainly regulated by
hormones such as glucocorticoids [10, 15], and activity
of this enzyme changes with age [16]. GA activity has
also been found in the muscle, but this activity is
probably attributed to the infiltration of other cell types
in this tissue [10, 17].
Glutamine transport in the muscle is performed by
the Nm system, which controls the concentration of
intramuscular glutamine and appears to be respon-
sible for both the outflow and inflow of glutamine.
This system is Na+ dependent and differs from the N
system in the liver by being pH independent. How-
ever, their activity is sensitive to insulin and glucocor-
ticoids [15, 17, 18].
Glutamine also participates in the synthesis of glyco-
gen in the muscle. In rats, intraperitoneal administration
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[19]. In humans that showed a decrease in glutamine
and muscle glycogen after exercise, an intravenous infu-
sion of glutamine increased the plasma concentrations
of this amino acid [20].
Glutamine: intestine metabolism
In intestinal epithelial cells, glutamine is quantitatively
the most important fuel. It is metabolized to glutamate,
which undergoes transamination, so the metabolites of
this reaction are oxidized in the TCA cycle to generate
pyruvate. Pyruvate then undergoes amination to produce
L-alanine via the action of alanine aminotransferase [7].
For many years, the intestine was investigated merely
as an organ of digestion, nutrient absorption, and fer-
mentation. However, it is now known that the intestine
is a complex organ that performs a diversity of critical
physiologic functions. The intestinal mucosa contains
secretory, immune, and neuroendocrine cells besides the
absorptive enterocytes [21]. Besides serving as a major
organ for nutrient digestion and absorption, the single
layer of epithelium lining the gastrointestinal tract
creates a selective barrier to prevent the transferring of
damaging agents as toxins, allergens, and pathogens to
the systemic blood circulation [22].
Newer research has shown since the studies conducted
by Windmueller and Spaeth in 1980 [23] that glutamine
is the main energy substrate of enterocytes. Rapidly
dividing cells require glutamine, as glutamine supplies of
half of nitrogen requirement for purine and pyrimidine
synthesis via action the carbamoyl phosphate synthetase
II within cytosol [24]. Glutamine is also a potential
precursor in the synthesis of N-acetyl-glucosamine and
N-acetyl-galactosamine, which may play a critical role in
the intestinal mucin synthesis and therefore for the
maintenance of passive barrier to bacterial invasion [25].
The entire gastrointestinal tract extracts around 20 %
of circulating post-absorptive glutamine, and over 90 %
of the glutamine extracted by the small intestine is
metabolized by mucosal cells [26]. The high absorptive
capacity in the apical region of enterocytes is the reason
this cells capture glutamine priority from the lumen, and
apparently, almost all glutamine contained in the diet is
utilized by the enterocytes [23]. The measurements of
intestinal glutamine metabolism also showed that
glutamine is the precursor for a number of important
metabolic pathways, especially those leading to the
synthesis of ornithine, citrulline, proline, and arginine.
Glutamine dipeptides induce mucosa proliferation of the
ileum and colon in human in vitro [27].
It has been reported that glutamine supplementation
increased villus height and area of the jejunum, but did
not alter the mass of protein or DNA 4-day old piglets
[21, 28]. Wu et al. [29] reported that a diet for weanedpigs supplemented with 1 % glutamine prevented atro-
phy of the villi of the jejunum. In 2011, Wu [30] demon-
strated that dietary glutamine supplementation prevents
jejunal atrophy in weaned piglets and glutamine supple-
mentation reversed the elevation of jejunal corticotropin-
releasing factor (CRF), which block the release of prote-
ases and TNF-α from mast cells in the jejunum, thereby
conferring a protective functional of the intestinal mucosa
[31]. According to Li and Neu et al. [32], glutamine
deprivation decreases the expression of claudin-1, a tightly
junction protein, and increases permeability in cultured
Caco-2 cells.
Glutamine: liver metabolism
The liver plays a central role in the nitrogen metabolism
in the body. Transportation of nitrogen is performed
mainly from the muscle and lung to the liver, as glutam-
ine, alanine, and aspartate. The breakdown of glutamine
releases NH3 that through mitochondrial enzymes enters
the urea cycle as a substrate. The urea cycle consumes
two molecules of ammonia and one molecule of carbon
dioxide, creates one molecule of urea, and regenerates a
molecule of ornithine for another turn. In the kidney,
the action of glutaminase produces the NH3 and because
that glutamine is quantitatively the most important
donor of NH3 in this tissue. In the collecting tubule,
NH3 combines with exported H
+ to form NH4
+, which is
excreted in the urine. Thereby, glutamine metabolism is
essential for acid-base buffering [33] and also plays an
important role in the biosynthesis of nucleotides, detoxi-
fication of ammonia, glutathione synthesis, and mainten-
ance of nitrogen transfer between organs [5, 12, 34].
GS and GA are present in the liver, with the GS being
expressed in perivenous hepatocytes and the GA in the
periportal zone [12]. Krebs [35] was the first to describe
hepatic metabolism of glutamine and hydrolysis of this
amino acid to glutamate and ammonia. In the liver,
glutamine metabolism is important in the regulation of
the urea cycle, detoxification of ammonia, and the pH
maintenance [12]. The glutamine transport can be
dependent upon Na+(ATB0, B0,+, y+L) and SNAT carriers
(sodium-coupled neutral amino acid transporter) of the
SLC38 gene family. Such carriers include SNAT2,
SNAT4, SNAT3, SNAT5, Lat2, and LAT1, and SNAT 3
and 5 are considered the most important in plasma
membrane of hepatocytes [12, 35, 36]. Studies have
shown the role of these transporters in the hepatic me-
tabolism and glutamine flow [37–39].
The role of FXR nuclear receptor in hepatic glutamine
has been also investigated. It is believed that this receptor
and its ligand are involved in the regulation of glutamine
and glutamate metabolism [40, 41]. Other studies have
highlighted the importance of hepatic metabolism of glu-
tamine in hepatic encephalopathy [42] and cancer [43].
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metabolism, many studies have investigated this amino
acid in liver injury situations [44–46]. In a study evaluat-
ing parenteral nutrition in premature infants, it was found
that parenteral glutamine supplementation was beneficial
to the liver in these individuals [46]. Previously, Wu et al.
[47] evaluated the effects of parenteral administration of
the alanyl-glutamine dipeptide in total parenteral nutrition
associated with liver damage in infant rabbits and ob-
served that this dipeptide supplementation can minimize
liver damage and reduce malondialdehyde (MDA) produc-
tion and hepatocyte apoptosis during total parenteral
nutrition.
Glutamine and immune response
Glutamine is typically included in the list of “immuno-
nutrients” that possess biological effects; glutamine is a
major fuel for many cells including lymphocytes, macro-
phages, fibroblasts in culture, and malignant cells [6].
For example, Newsholme and Parry-Billings [9] demon-
strated a close relationship between the rate of phagocyt-
osis in murine macrophages and glutamine concentrations.
Macrophages are metabolically active cells, characterized
by high rates of protein secretion and membrane recycling.
Accordingly, macrophages are dependent upon extra-
cellular sources of glutamine [6, 48]. The maintenance
of glutamine plasma concentrations has considerable
influence on the function of some cells and tissues. It
has been described in the literature that decreased
glutamine plasma concentrations may have important
influences on the lymphoid system, as well as the
function of macrophages [6, 48].
Ogle et al. [49] found that in cells from burn patients,
addition of glutamine in neutrophils improved the
neutrophil bactericidal function. With glutamine, neu-
trophils were better able to kill Staphylococcus aureus.
Glutamine addition resulted in restoration of cell function
to normal levels. Furthermore, glutamine is important to
the maintenance of functional integrity mitochondrial and
the ATP production, protecting the neutrophils from
apoptosis.
Cells of the immune system have higher glutamine
requirements during inflammatory states such as sepsis
and injury. As the consequence of the increased require-
ment, the demand for this nutrient may exceed produc-
tion, leading to an imbalance. As a result, the bloodstream
and tissue concentrations fall. These low concentrations
of glutamine limit the ability of various tissues to achieve
optimal function, especially for immunological tissues.
Plasma glutamine concentrations reflect only the environ-
ment of cells in the lymph nodes or in the spleen, which
are adjacent to the capillaries. As glutamine is extracted
from the extracellular fluid, cells located a greater distance
from the capillaries are exposed to a reduced glutamineconcentration compared to the plasma. Kupffer cells may
also be exposed to lower glutamine concentrations than
observed in the plasma because their sinusoidal arrange-
ment within the hepatic lobule does not allow all cells to
come into direct contact with circulating blood. In
addition, the blood supply to the liver via the portal sys-
tem has a lower glutamine concentration because the
small bowel has already extracted some of the glutam-
ine for its own use. Therefore, based on the present
knowledge, immunologic tissue is compromised by
low concentrations of glutamine [6, 50].
Glutamine: critical illness
The systemic inflammatory response syndrome (SIRS)
and the compensatory inflammatory response syndrome
(CARS) were conceptually described in the 1990s [51].
SIRS are nonspecific and may or may not be related to
infections by pathogens and is defined by the following
clinical criteria: fever greater than 38 °C or less than 36 °C;
heart rate >90 beats per minute; respiratory rate >20
breaths per minute and leukocytes >12,000/uL or <4000/
uL or >10 % immature forms [52, 53]. The consensus for
severe sepsis definition includes, among other factors, the
presence of two or more criteria for SIRS; however, a
recent study addressed cases of individuals with SIRS-
negative severe sepsis [53]. Moreover, recently, the
definition of sepsis was revised, the new definition consist
in a systemic response to infection with the presence of
some degree of organ dysfunction [53, 54].
The major pro-inflammatory factors that contribute to
SIRS are TNFα, IL-1, neutrophil degranulation products,
coagulation factors, platelet-activating factor and arachi-
donic acid derivatives, and others [52]. As with SIRS,
CARS is a complex immune response involving anti-
inflammatory and immunosuppressive mechanisms that
are able to restore homeostasis after injury and SIRS or, if
unchecked leads to a state of profound immunosuppres-
sion, predisposing the individual to infections [52, 55].
Mixed anti-inflammatory response syndrome (MARS)
represents the transition from SIRS to CARS followed
by homeostasis or predominance of one over the other
[52] and even switching between the increase and
decrease of anti- and pro-inflammatory mediators [56].
In the context of regulation of the immune system, the
role of nutrients and bioactive compounds in the
modulation of inflammatory responses is often dis-
cussed [57–59]. In recent decades, the immunomodu-
latory potential of glutamine has been demonstrated
[59] as being essential for metabolism of immune cells
such as neutrophils, lymphocytes, and macrophages which
in some cases use more glutamine than glucose [5, 7, 59].
Additionally, glutamine is a precursor to glutathione
which is responsible for preventing oxidative stress by
reacting directly with reactive oxygen species [60, 61].
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concentration affects the redox state and the metabolism
of cells of the immune system, resulting in compromised
immune response contributing to the development of
sepsis. Thus, studies have evaluated the benefits of main-
taining glutamine concentration in critically ill patients
[62–64], especially in cases related to inflammatory
response syndrome (SIRS) and sepsis [65–68]. Studies
have been performed in an attempt to gather data demon-
strating the effectiveness of glutamine supplementation in
critically ill patients [62, 63]. Lin et al. [62] concluded that
in glutamine supplementation for burn patients, a signifi-
cant decrease in mortality and in the number of individuals
infected with gram-negative bacteria was seen. Bollhalder
et al. [63] analyzed the effects of parenteral nutrition with
glutamine in randomized trials and concluded that supple-
mentation decreased the length of hospital stay and the
occurrence of infectious diseases. However, both studies
had methodological inconsistencies such as start and time
of supplementation, glutamine dose, disease severity,
among other factors, and more clinical trials are needed to
assess the effectiveness of glutamine supplementation in
critically ill patients.
Recent research has shown that septic patients are
usually hypercatabolic. Because of the impairment of the
ability to use glucose and fat, there is an increasing
dependency on muscle breakdown, providing essential
substrates for acute phase protein synthesis and energy
production [69]. Glutamine requirements increase
markedly, and its utilization may exceed endogenous
production [51, 70]. Glutamine depletion decreases
proliferation of lymphocytes, influences expression of
surface activation markers on lymphocytes, affects the
production of cytokines, and induces apoptosis [71].
Contrary to the benefits of glutamine in critically ill
patients, a randomized clinical trial evaluating 1223
adult patients undergoing mechanical ventilation, with
failure of multiple organs receiving high doses of
glutamine (30 g/day), antioxidants, glutamine and
antioxidants, or placebo, revealed that glutamine supple-
mentation was associated to increased mortality in these
individuals [72, 73]. The authors attribute the difference
in the results obtained in relation to literature to factors
such as doses, route of administration, patient status,
start of supplementation, and also the possibility of
publications bias, once conclusions about the benefits of
supplemental glutamine in critically ill patients started
from meta-analyzes with small numbers of clinical trials,
methodologically less robust [72].
However, those results are still controversial, and it is
important to consider the timing of glutamine adminis-
tration. In studies where glutamine was administered be-
fore the onset of infection, it prevented the infection,
both in animals and in humans. This is most likely bymaintaining glutamine concentrations and preventing a
state of glutamine deficiency. Therefore, such patients
are protected from the inadequacies of present day
conventional nutrition, which makes them susceptible to
infections [74].
Given the lack of full knowledge and the necessity to
clarify some beneficial effects of glutamine supplementa-
tion in critically ill patients, this highlights the need to
conduct more well-designed clinical studies.
Molecular mechanism and gene expression
Heat shock protein
Heat shock proteins (HSPs) are a family of highly con-
served intracellular “housekeeping” proteins that maintain
cell function [75]. They exert roles in antigen presentation,
activation of lymphocytes and macrophages, and activa-
tion and maturation of dendritic cells, as well as acting as
a stimulator of pro-inflammatory cytokine production.
Thus, it has been suggested that HSPs provide the link
between innate and adaptive immune systems [76]. HSP-
70, one of the members of the HSP protein family, has
powerful immune regulatory effects, providing cellular
protection by preventing apoptosis and cell death. Under
physiological circumstances, HSP-70 is detectable in
plasma of healthy individuals, suggesting that during times
of homeostasis, HSP-70 does not promote an inflamma-
tory response and its immune regulatory/inflammatory
functions are tightly controlled [75].
A model of sepsis, in vitro, reported that glutamine
promoted HSP70 release, and addition of 2 mM glutam-
ine significantly increased HSP-70 levels and promoted
an early pro-inflammatory response [75]. In accordance
with that, Jordan et al. [77] showed that in critically ill
children after 5 days of glutamine supplementation,
there was a remarkably higher level of HSP-70, in com-
parison with the sharp decline observed in control
group.
Mitogen-activated protein kinases
Mitogen-activated protein kinases (MAPKs) are protein
Ser/Thr kinases that convert extracellular stimuli into a
wide range of cellular responses. MAPK pathways coor-
dinately regulate gene expression, mitosis, metabolism,
motility, survival, apoptosis, and differentiation [78].
Glutamine uptake is enhanced in activated lymphocytes.
ERK signaling, a MAPK family member, is required for
enhanced glutamine uptake and increased activity of key
metabolic enzymes. Carr et al. [79] showed that glutamine
uptake is blocked in lymphocytes when ERK was inhib-
ited, thus demonstrating that in these cells, ERK is a
central player in cellular metabolic control. In addition,
glutamine inactivates p38 and JNK and exhibits a protect-
ive effect against endotoxic shock when administered after
LPS injection [80].
Fig. 2 Representation of the nuclear factor kappa B (NF-kB) pathway
activation. An external inflammatory signal activates the signaling
pathway, leading to the phosphorylation of proteins that culminated
in the IKB activation and degradation, allowing the NF-kB to migrate
to the nucleus and binding to specific regions of the DNA
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via deactivating cytosolic phospholipase A2 (cPLA2).
Glutamine indirectly deactivates cPLA2 by dephosphory-
lating p38 MAPK, the major kinase for cPLA2 phosphor-
ylation, through inducing MAPK phosphatase-1 (MKP-1).
Lee et al. demonstrated a physical interaction between
glutamine-induced MKP-1 and pcPLA2, suggesting that
glutamine can directly deactivate cPLA2 via early induc-
tion of MKP-1 [81].
Zhu et al. [82] demonstrated that glutamine deprivation
induced autophagy, disturbed amino acid metabolism, and
inactivated mTOR and MAPK/ERK signaling pathways in
porcine intestinal epithelial cells-1 (IPEC-1). In addition,
supplementation with 5 mM of glutamine is able to in-
crease ERK1/2 phosphorylation in IPEC-1. Thus, glutamine
supplementation suppresses autophagy, increases cellular
protein content, and promotes cell proliferation.
Nuclear factor-Kb
The nuclear factor kappa B (NF-kB) signaling pathway
serves a crucial role in regulating the transcriptional re-
sponses of physiological processes including cell division,
cell survival, differentiation, immunity, and inflammation
[83]. The IkB family of inhibitory proteins sequester in-
active NF-kB in the cytosol, therefore regulating NF-kB
dimers. Activation of NF-kB/Rel proteins therefore
requires degradation of IkB proteins via ubiquitin-
mediated proteolysis to initiate nuclear translocation and
DNA binding of active NF-kB/Rel complexes [84].
The central role of NF-kB in both innate and adaptive
immunity is mediated by the coordinate expression of
multiple genes essential for the immune response. The im-
portance of NF-kB is revealed by the extensive list of NF-
kB-inducible genes, including those for pro-inflammatory
cytokines such as IL-1, IL-6, and TNF-α as well as chemo-
kines [85] (Fig. 2).
Oral supplementation with glutamine (1 g/kg) plus
L-alanine (0.61 g/kg) or 1.49 g/kg L-alanyl-L-glutamine
dipeptide was able to attenuate total NF-kB p65 expres-
sion in mouse gastrocnemius skeletal muscle after LPS
stimulation in an animal sepsis model promoting anti-
inflammatory effects via the NF-kB pathway [86].
There is evidence for redox imbalance and oxidative
stress in human sepsis, as demonstrated by increased
markers of oxidative damage with higher activation of
NF-kB [87, 88]. Glutamine appears to be one of the anti-
oxidants of possible clinical benefit. It is the most abun-
dant amino acid in the body, and it is an important
precursor of glutathione (GSH). Its supplementation in
enteral and parenteral nutrition solutions can be used to
maintain high levels of GSH and prevent oxidative
stress-induced damage [88]. Glutamine treatment in a
model of non-alcoholic fatty liver disease decreased NF-
kB activation, and it was able to mediate the reducedtranscription of downstream inflammatory factors,
thereby decreasing hepatic damage and reducing ROS
generation, alleviating the oxidative stress of the liver
cells [89].
Macrophages supplemented with glutamine have
revealed that stimulation with LPS increased NF-kB acti-
vation under 2 and 10 mM of glutamine supplementation
in comparison to macrophages treated with 0 and 0.6 mM
of glutamine, as examined by DNA binding activity of NF-
kB using an electrophoretic mobility shift assay (EMSA)
[90]. Alternatively, da Silva et al. [91] demonstrated lower
expression of phosphorylated NF-kB in macrophages cul-
tivated with higher concentrations of glutamine and stim-
ulated with LPS, showing that glutamine negatively
regulated NF-kB signaling pathway.
Role of glutamine on cell migration and adhesion molecules
Several studies have demonstrated the influence of
glutamine on cell migration and adhesion molecules.
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then either supplemented with glutamine or received a
control diet. Both groups exhibited mucosal ulceration,
gland distortion, and leukocyte infiltration, but pre-
treatment with glutamine reduced leukocyte infiltration
to tissues and resulted in less severe mucosal inflamma-
tion compared to animals without the addition of
glutamine.
A study examining early-weaned mice (at the age of
14 days) and intraperitoneally inoculated with BCG
(Mycobacterium bovis cepa Moreau) reported that glu-
tamine supplementation increased leukocytes, lympho-
cytes, and neutrophils in the peripheral blood, while
BCG inoculation reduced the percentage of lymphocyte
and increased the count and percentage of neutrophils.
Both in the spleen and in the bone marrow, glutamine
supplementation led to an increase in granulocytes and
lymphocytes. Thereby, the authors evidenced that the
function of macrophages and hemopoiesis were
increased by the intake of glutamine-supplemented diet
in early-weaned and BCG-inoculated mice [93]. In
addition, Kim et al. [94] indicated that glutamine dose-
dependently enhanced migration of immortalized human
dental pulp cells (HDPCs). They also demonstrated that
glutamine favors growth, migration, and differentiation
in HDPCs through the BMP-2, Wnt, and MAPK path-
ways, developing a better response in pulp repair and
regeneration.
Zou et al. [95] evaluated the potential function of GS
in reactive astrocytes at the site of mechanical spinal
cord injury. Using siRNA-mediated GS knock-down to
suppress astrocytic GS, the authors demonstrated
increased cell migration into the scratch wound zone
and decreased substrate adhesion. In addition, they
showed that glutamine-enhanced migration and glutam-
ate suppressed it. Glutamine is also known to regulate
the expression of extracellular matrix ligands and their
receptors. This may explain the increased motility
observed in the presence of exogenous glutamine since
the GS-silenced astrocytes express a considerably lower
affinity for the extracellular matrix (ECM).
Adhesion molecules and chemokine receptors strictly
regulate leukocyte migration to specific tissues through
several mechanisms. Adhesion molecules present on the
vascular endothelium allow leukocytes to tether, roll,
and adhere [96]. The expressions of those molecules are
upregulated by proinflammatory cytokines (TNF-α and
IL-1) and NF-kB pathway [97].
Rogero et al. (2008) [93] investigated how glutamine
supplementation in early weaning (EW) mice influences
the adhesion capacity of peritoneal macrophages. EW
macrophages have a decreased ability to adhere when
compared with the control group, but glutamine supple-
mentation at 1 and 2 mM were capable of reversing thiseffect. EW macrophages also showed less spreading abil-
ity when compared to the control group, an effect that
was reversed by in vitro glutamine supplementation.
Rogero et al. [98] found that early weaning was associ-
ated with reduced glutamine ingestion which negatively
affected the peritoneal macrophage adhesion, phagocyt-
osis, fungicidal activity, and synthesis of NO, H2O2, and
pro-inflammatory cytokines. Opsonization and phago-
cytic capacity are increased during inflammation when
macrophages and monocytes are able to adhere to the
extracellular matrix. Therefore, they hypothesized that
the decreased phagocytic and fungicidal activities and
the lower synthesis of TNF-α in the absence of glutam-
ine is associated with diminished adhesion observed in
peritoneal macrophages. However, it is necessary to
define if the modulation caused by glutamine is due to
its metabolism in these cells or their substrates gener-
ated by various biochemical pathways, or else the effect
of direct or indirect action of this amino acid on the ex-
pression of genes involved in phagocytosis or inflamma-
tory processes [98, 99].
Yeh et al. [100] analyzed the impact of dietary glutam-
ine supplementation in adhesion molecules in mice with
sepsis induced by cecal ligation and puncture (CLP).
The progression of sepsis raised the concentrations of
intracellular adhesion molecule-1 (ICAM-1) reaching
the maximum at 12 and then declining by 24 h after
CLP. The glutamine group displayed significantly lower
plasma ICAM-1 levels at 6, 12, and 24 h after CLP com-
pared with the control group. This group also exhibited
higher expression of lymphocyte CD11a/CD18 and
lower PMN expressions of CD11b/CD18. So, under a
septic condition, glutamine administration may improve
lymphocyte function, decreased PMN–endothelium in-
teractions, and thus may diminish neutrophil infiltration
into tissues.
Hou et al. 2014 [96] showed that adhesion molecules
(PSGL-1 and CD 11a) and C-C chemokine receptor type
9 (CCR9) on Th cells and cytotoxic T cells significantly
increased in both blood and mesenteric lymph nodes
after induced colitis. Oral glutamine administration
suppressed T cell expression of adhesion molecules and
CCR9, downregulated the mRNA levels of adhesion
molecules expressed by endothelium in colon tissues,
and suppressed Th-cell infiltration into the colonic
mucosa.
A study investigated the effect of parenteral glutamine
supplementation on leukocyte integrin expression and
immune cell recruitment after gastrectomy in Wistar
rats. Surgery promoted higher CD11b/CD18 expression
in polymorphonuclear leukocytes, and glutamine supple-
mentation decreased CD11b/CD18 expression. Add-
itionally, 3 days after surgery, more neutrophils were
recruited to the site of injury, and both glutamine as
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with lower CD11b/CD18 expression than those on post-
operative day 1 Sham group [101].
Other researchers evaluated the effects of glutamine
supplementation in adhesion molecules in diabetic mice.
Soluble adhesion molecule levels in diabetic patients are
significantly higher than those in healthy controls, and
excessive expression of adhesion molecules may induce
an inflammatory response and tissue injury. Diabetic
mice had higher concentrations of ICAM-1 and VCAM-
1 than the normal group, but glutamine did not affect
ICAM-1 and VCAM-1 level in the diabetic group.
However, glutamine lowered CD11a/CD18 expression in
the diabetic group (with or without glutamine). Thus, in
a diabetic condition, leukocyte adhesion may be de-
creased when glutamine is administered [102, 103].
Human cells were also evaluated in the presence or
the absence of glutamine in some studies. Spittler et al.
[104] demonstrated for the first time that glutamine
concentration in cell culture could affect the expression
of several antigens on human monocytes.
With the aim to better understand the effect of
glutamine in the treatment of sickle cell anemia, the
adhesion of sickle RBC to human umbilical vein endo-
thelial cells (HUVEC) was determined. Oral L-glutamine
therapy significantly reduced adhesion of sickle RBC to
HUVEC in both assays with autologous plasma-
incubated cells and LPS-incubated cells, similar to the
levels in healthy control. This effect may be explained by
improvement of NAD redox potential of sickle RBC,
which prevents oxidant damage, therefore decreasing
stimulation of inflammation and expression of adhesion
molecules [102].
In contrast with the other findings, a study performed
with seven different concentrations between 0.05 and
2 mM of glutamine revealed that low concentrations of
glutamine express significantly less CR4 (CD11c/CD18),
CR3 (Mac-l, CD11b/CD18), and ICAM-1/CD54 than
monocytes cultured with higher concentrations [103].
Over time, many studies have been demonstrated the
importance of glutamine concentration in cell migration
and the expression of adhesion molecules. Although
most studies have demonstrated that the presence of
glutamine decreased cellular infiltrates in tissues and re-
duced the expression of adhesion molecules, there are still
controversial data. This can be explained by the use of dif-
ferent cell types, concentrations, time, and model study.
The mechanisms by which glutamine modulates these pa-
rameters still need to be studied in order to improve
understanding.
Conclusions
Glutamine supplementation leads to a range of reactions
and modulatory effects of processes across differentorganisms. Although many studies have unveiled and
evaluated the glutamine effects in numerous biological
processes, further studies are necessary to provide
information about safe dose usage of glutamine supple-
mentation in patients.
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